JP Morgan Maintains Neutral on Cerevel Therapeutics Hldg, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye has maintained a Neutral rating on Cerevel Therapeutics Holdings (CERE) but increased the price target from $25 to $45.
December 28, 2023 | 10:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan has maintained a Neutral rating on Cerevel Therapeutics Holdings but raised the price target from $25 to $45, indicating a positive outlook on the company's future performance.
The increase in price target from $25 to $45 by a major analyst like JP Morgan suggests a more positive outlook on the company's value and potential growth, which could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100